


Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1 (Original) A compound of formula I:



where n is 2, 3 or 4;

Ar¹ represents phenyl or heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, C₁-₄alkoxy or C₁-₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁-₄alkoxy;

Ar² represents phenyl or heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, C₁-₄alkoxy or C₁-₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁-₄alkoxy;


R¹ represents C₁-₄alkyl, or together with R² completes a pyrrolidine, piperidine or homopiperidine ring;

R² represents H or C₁-₆alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁-₄alkoxy; or together with R¹ completes a pyrrolidine, piperidine or homopiperidine ring; or together with R³ completes a tetrahydroisothiazole-1,1-dioxide ring; and

R³ represents phenyl, naphthyl or heteroaryl, any of which may bear up to 3 substituents selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, C₁-₄alkoxy, C₁-₄alkoxycarbonyl, C₂-₆acyl, C₂-₆acyloxy, C₂-₆acylamino, amino, C₁-₄alkylamino, di(C₁-₄alkyl)amino or C₁-₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁-₄alkoxy; or R³ represents CF₃ or a non-aromatic hydrocarbon group of up to 6 carbon atoms optionally bearing one substituent selected from halogen, CN, CF₃, OH, OCF₃, C₁-₄alkoxy, C₁-₄alkoxycarbonyl, C₂-₆acyl, C₂-₆acyloxy, C₂-₆acylamino, amino, C₁-₄alkylamino, di(C₁-₄alkyl)amino or phenyl, naphthyl or heteroaryl, any of which may bear up to 3 substituents selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, C₁-₄alkoxy, C₁-₄alkoxycarbonyl, C₂-₆acyl, C₂-₆acyloxy, C₂-₆acylamino, amino, C₁-₄alkylamino, di(C₁-₄alkyl)amino or C₁-₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁-₄alkoxy; or R³ together with R² completes a tetrahydroisothiazole-1,1-dioxide ring;

or a pharmaceutically acceptable salt thereof.


Claim 2 (Original) A compound according to claim 1 of formula II:



II

where n, Ar¹, Ar², R² and R³ are as defined in claim 1;
or a pharmaceutically acceptable salt thereof.

Claim 3 (Original) A compound according to claim 1 of formula III:



III

wherein m is 1, 2 or 3;

R³ᵃ represents R³ which does not form a ring with R²;

and Ar¹, Ar² and R³ are as defined in claim 1;

or a pharmaceutically acceptable salt thereof.

Claim 4 (Amended) A compound according to ~~any previous claim 1~~ wherein Ar¹ is 4-chlorophenyl or 4-trifluoromethylphenyl and Ar² is 2,5-difluorophenyl.

Claim 5 (Amended) A pharmaceutical composition comprising a compound according to ~~any previous claim 1~~, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Claims 6-7 (Canceled)


~~Claim 8~~ (Amended) A method of treatment of a subject suffering from ~~or prone to a condition associated with the deposition of β-amyloid~~ ^{Alzheimer's Disease} which comprises administering to that subject an effective amount of a compound according to ~~any of claims 1-4~~ claim 1 or a pharmaceutically acceptable salt thereof.

~~Claim 9~~ (Original) A method of preparing a compound according to claim 1 in which R² does not form a ring with R³ comprising reaction of an amine (IV) with R³ᵃ-SO₂Cl:



R^{3a} represents R^3 which does not complete a ring with R^2 , and n , Ar^1 , Ar^2 , R^1 , R^2 and R^3 are as defined in claim 1.

8



where n, Ar¹, Ar² and R¹ are as defined in claim 1, with L-(CH₂)₃-SO₂Cl where L represents a leaving group, followed by intramolecular alkylation of the resulting sulphonamide nitrogen.